Skip To Main Content
Shan Fu on Muck Rack

Shan Fu

As seen in: Nature, Frontiers, The BMJ, JAMA Oncology

Get in touch with Shan

Contact Shan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Ultralow-Dose Interleukin 10–Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma : A Nonrandomized Clinical Trial

|
By Yongxian Hu, Mingming Zhang, Min Gao, Shan Fu, Yiling Li, Jingjing Feng, Ruimin Hong, Guoqing Wei, Duoduo Zhao, Jiazhen Cui, Simao Huang, Jingjing Ren, Youjia Li, Qian Chen, Zhan Zhou, Dongrui Wang, Yugang Guo, Li Tang, Xingbing Wang, He Huang, Yetian Dong, Xunuo Zhu, Daojun Bai, Baoyun Cheng, Yuanbin Cui, Chongling Liu
| JAMA Oncology Verified
Ultralow-Dose Interleukin 10–Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial Key Points Question What is the safety and efficacy of interleukin 10–expressing CD19 chimeric antigen receptor (CAR) T cells (META 10-19) in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
Open in Who Shared Issue with article?

Prevalence of sarcopenic obesity in adult patients with diabetes and associated factors: a systematic review and meta-analysis

|
By Feng Chen, Ke Zhou, Qingyun Li, Shan Fu, Zheng Shi, Shiyun Li, Rong Peng, Zixue Gu, Changwei Mou
| Frontiers
Abstract Objective: This systematic review and meta-analysis aimed to estimate the prevalence of sarcopenic obesity (SO) among adults with diabetes and summarize associated factors.
Open in Who Shared Issue with article?

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia

|
By Mingming Zhang, Lianxuan Liu, Shan Fu, Jingjing Feng, Haiqiong Zheng, Guoqing Wei, Ruimin Hong, Houli Zhao, Huijun Xu, Jiazhen Cui, Simao Huang, Xiaoyu Wu, Dongrui Wang, Alex Chang, He Huang, Yongxian Hu
| Nature Verified
Abstract Although CAR-T cell therapy has revolutionized treatment for hematologic malignancies, its application in acute myeloid leukemia remains challenging. CD7 is expressed in approximately 30% of AML cases and represents a promising target. This phase I clinical trial (NCT04599556) evaluated CD7-targeted CAR-T cell therapy in patients with relapsed/refractory CD7-positive AML.
Open in Who Shared Issue with article?
See all 5 articles